Developmental and Epileptic Encephalopathies (DEEs) are a group of rare and severe epilepsies which are characterized by seizures and significant developmental delays. Most DEEs begin in early life, often in infancy, with children experiencing frequent and severe seizures, which can be of multiple types. This generates a complex clinical picture in which both developmental abnormalities and severe epilepsy contribute to the functional impairment of these children which continues into adulthood. In this video, watch Mat Davis, PhD, Vice President, Head of Data Science, Evidence and Value Generation, discuss how we leverage focused and integrated quantitative methods in our R&D process to transform patient lives.
Transforming Lives.
Redefining Possibilities.
Perspectives
The Power of Real-World Evidence In Rare and Difficult-to-treat Epilepsies
Perspectives
Differentiating Jazz’s R&D Expertise Through Quantitative Drug Development
News and Events
Sep 9, 2024
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
Living Our Values
Clinical Trials
By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.